Drug recall · January 3, 2018
Neostigmine Methylsulfate 5 mg/5 mL recall
Why: Lack of sterility assurance: Microbial growth detected during a routine simulation of the manufacturing process. No batches of distributed product have been identified as actually containing microorganisms.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Neostigmine Methylsulfate 5 mg/5 mL, 5 mL Syringe, Concentration: 1 mg/mL. This is a compounded injectable drug; Rx only; Hospital/office use only. SSM St. Clare Outsourcing Facility, Fenton, MO --- NDC: 88890-0329-01
- Lots / codes
Lot: 170705-002, 10/03/2017
- Quantity
- N/A
- Company
- SSM Health Care St. Louis DBA SSM St. Clare Health Center, Fenton, MO
- Distribution
- SSM Health entities in the state of MO only
- Initiated
- August 10, 2017 · Voluntary: Firm initiated
- Classified
- December 28, 2017
- Reported
- January 3, 2018
- Ended
- March 22, 2018
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Neostigmine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.